US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Patrik Tolf

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    +46 31 766 90 21
    http://www.vitrolifegroup.com
  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Vitrolife has received order for 20 EmbryoScope+ to leading clinic in China

    In March, Vitrolife AB (publ) received market approval for the time-lapse incubator EmbryoScope+ in China. The company has now received order for 20 EmbryoScope+ to be installed at a leading clinic in China during the second quarter. The order is the largest single order for EmbryoScope+ so far for Vitrolife.EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. In March, Vitrolife received market

    Vitrolife acquires artificial intelligence technology for embryo assessment

    Vitrolife has acquired rights to a technology for assessing embryos based on time-lapse videos using artificial intelligence (“AI”) and entered into collaboration agreements to further develop the technology.Vitrolife has entered into transfer and collaboration agreements regarding a technology for assessing embryos with Virtus Health, a leading IVF clinic group based in Australia and Harrison.AI, a technology company specialising in the development of AI software in healthcare applications based in Australia. Using time-lapse videos during in vitro fertilisation (IVF), and before embryo

    EmbryoScope+ approved for sales in the USA

    Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope+ in the USA, the world's third largest market measured in terms of number of IVF treatments.EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. “We are delighted to now being able to offer also EmbryoScope+ to the clinics in the USA”, says Thomas Axelsson, CEO of Vitrolife. May 12, 2018Gothenburg

    EmbryoScope approved for sales in China

    Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope in China and thereby becomes the first company to market an approved time-lapse incubator in the world´s largest IVF market.EmbryoScope is a time-lapse system with an integrated incubator with a capacity for six patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. “There is a great interest for time-lapse in China and we are delighted to now being able to offer EmbryoScope to the clinics in China”

    Kato Ladies Clinic chooses EmbryoScope+ for improved IVF treatments

    Kato Ladies Clinic in Japan, one of the world´s largest IVF clinics, has decided to invest in the newly launched time-lapse system EmbryoScope+. The order comprises eight EmbryoScope+ time-lapse incubators providing the Kato Ladies Clinic with a time-lapse capacity of approximately 6000 treatments per year, making it the largest time-lapse capacity in a single clinic in the world.The first units will be installed during the fourth quarter 2016 and the remaining units are planned to be installed during the first quarter 2017. Kato Ladies Clinic and Vitrolife have also agreed to perform a

    Interim report January-June 2016: Good growth and broadened product portfolio

    Second quarter: · Sales amounted to SEK 208 (184) million, corresponding to an increase of 13 percent in SEK. Net sales growth was 15 percent in local currency. · Operating income before depreciation and amortisation (EBITDA) amounted to SEK 74 (62) million, corresponding to a margin of 35 (34) percent. · Net income amounted to SEK 48 (39) million, which gave earnings per share of SEK 2.21 (1.77). · Acquisition of all the shares in OCTAX and MTG, world-leaders in the field of laser technology for IVF. · Vitrolife introduces EmbryoScope+ and broadens the time-lapse product

    Vitrolife introduces EmbryoScope+ and broadens time-lapse portfolio

    Vitrolife is the market leader of time-lapse systems for use in assisted reproduction. With the introduction of EmbryoScope+, the company can offer an additional high quality time-lapse system for undisturbed culture and improved selection of embryos. EmbryoScope+ has a large capacity in combination with a small footprint, providing an efficient workflow and optimised usage of clinic resources. The product will be introduced at the upcoming ESHRE conference next week in Helsinki, Finland.EmbryoScope+ is a time-lapse system with an integrated incubator. EmbryoScope+ builds on the same

    Interim report January-September 2015: Increased organic growth

    Third quarter: · Sales amounted to SEK 177 (125) million, corresponding to an increase of 41 percent in SEK. Sales growth was 29 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 25 million to sales. Adjusted for this, sales growth amounted to 11 percent in local currency. · Operating income before depreciation and amortization (EBITDA) amounted to SEK 82 (49) million, corresponding to a margin of 46 (39) percent. Income was positively affected by the recovered additional purchase price for the acquisition of Cryo

    Interim report January-June 2015: Good growth and strengthened income

    Second quarter: · Sales amounted to SEK 184 (129) million, corresponding to an increase of 42 percent in SEK. Sales growth was 27 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 32 million to sales. Adjusted for this, sales growth amounted to 5 percent in local currency. · Operating income before depreciation and amortization (EBITDA) amounted to SEK 62 (38) million, corresponding to a margin of 34 (29) percent. Fluctuations in exchange rates had a positive effect of SEK 9 million on EBITDA. · Net income amounted to

    Report on operations 2014: Acquisition of FertiliTech and strengthened income

    Fourth quarter · Acquisition of all the shares in Unisense FertiliTech A/S (“FertiliTech”), the market leader in embryo monitoring, time-lapse, for IVF. · Non-cash issue of 1,879,179 shares for part-financing of the acquisition of FertiliTech. · Sales amounted to SEK 137 (124) million, corresponding to an increase of 11 percent in SEK. Sales growth was 4 percent in local currency. Last year’s figure included sales of the transplant product STEEN Solution™ to Xvivo to the tune of SEK 5 million. Adjusted for this, the increase in sales amounted to 8 percent in local currency. ·

    Vitrolife’s share capital and number of shares on November 28, 2014

    As per November 28, 2014, the total number of shares in Vitrolife AB (publ) amounts to 21,710,115, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 22,144,317.30.At the beginning of the month the total number of shares in the company amounted to 19,830,936, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 20,227,554.72. The increase in the number of shares by 1,879,179 during the month of November is due to the non-cash issue of shares with regards to the acquisition of Unisense FertiliTech A/S. November 28, 2014Gothenburg

    Vitrolife AB (publ) acquires Unisense FertiliTech A/S

    Vitrolife AB has entered into an agreement to acquire all the shares of Unisense FertiliTech A/S (“FertiliTech”), the market leader within the field of embryo monitoring, time-lapse, for IVF.Description of FertiliTechFertiliTech has driven the clinical use of time-lapse imaging for IVF. Their products have been used in more than 200.000 IVF treatments in 47 countries. FertiliTech has its head office in Århus, Danmark. The company was formed in 2003 and has approximately 70 employees. FertiliTech and its subsidiaries had net sales of approximately SEK 94 million in 2013 and reported income

    Interim report January-June 2014: Strengthened income and high growth

    Second quarter: · Sales growth was 9 percent in local currency. Sales amounted to SEK 129 (116) million, corresponding to an increase of 12 percent in SEK. Last year’s figure included sales of STEEN Solution™ to Xvivo to the tune of SEK 3 million. Adjusted for this, the increase in sales amounted to 12 percent in local currency. · Vitrolife launched the company’s new culture media for time-lapse, G-TL™. · Operating income (EBIT) amounted to SEK 34 (19) million, corresponding to an operating margin of 26 (16) percent. · Net income amounted to SEK 23 (12) million, which gave

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January - March 2014. The presentation will be held in English.Time: Wednesday, April 23, 2014 at 10.00 a.m. CET.  Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=190307 or shortly before time of the conference starts on: Sweden dial in number: +46 (0)8 5052 01 10UK dial in number: +44 (0)20 7162 0077Conference name: Vitrolife, conference ID: 944026 Vitrolife

    Report on operations 2013: High growth and improved profitability

    Fourth quarter Continuing operations: · Sales growth was 27 percent in local currency. Sales amounted to SEK 124 (98) million, corresponding to an increase of 26 percent in SEK. · Operating income (EBIT) amounted to SEK 22 (12) million, corresponding to an operating margin of 18 (12) percent. The quarter was affected by the write-down of intangible assets with regard to Labware to the tune of SEK 9 (-) million. · The comparative figures for 2012 relate to continuing operations, Fertility, unless otherwise stated. · Net income amounted to SEK 15 (0) million, which gave

    Report from Annual General Meeting of Vitrolife AB (publ)

    At Vitrolife’s Annual General Meeting yesterday, April 29, the following, amongst other things, was decided: · The Board’s proposed dividend of SEK 0.60 per share for the financial year 2012 was approved. Friday May 3, 2013 was adopted as the record day. · Re-election of Board members Fredrik Mattsson, Tord Lendau, Maris Hartmanis, Barbro Fridén and Carsten Browall and new election of Pia Marions, in accordance with the election committee’s proposal. Carsten Browall was elected Chairman of the Board. · Remuneration to the members of the Board shall be totalling SEK 900,000,

    Interim report January-March 2013: High growth and increased income

    First quarter Continuing operations: · Sales growth was 27 percent in local currency. Sales amounted to SEK 105 (86) million, corresponding to an increase of 22 percent in SEK. · Operating income (EBIT) amounted to SEK 17 (10) million, corresponding to an operating margin of 16 (12) percent. · Net income amounted to SEK 12 (7) million, which gave earnings per share of SEK 0.61 (0.38). After the end of the period · During 2010 Vitrolife entered into a collaboration agreement with the Danish company HertArt ApS with a view to developing a new range of disposable plastic

    Conference call interim report

    Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January - March 2013. The presentation will be held in English.Time: Friday, April 19, 2013 at 10 a.m. CET. Registration can preferably be done in advance under the following link: https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=187229 or shortly before the conference starts on: Sweden dial in number: +46 (0)8 5052 0110 UK dial in number: +44 (0)20 7162 0077 Conference name: Vitrolife, conference ID: 931066 Vitrolife participants:Thomas

    Vitrolife’s share capital and number of shares on November 30, 2012

    As per November 30, 2012, the total number of shares in Vitrolife AB (publ) amounts to 19,830,936, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 20,227,554.74.At the beginning of the month the total number of shares in the company amounted to 19,562,769, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 19,954,024.38 The increase in the number of shares by 268.167 during the month of November is due to the private placement that was directed to the previous owners of Cryo Management Ltd to partly finance the acquisition of Cryo

    Interim report January – September 2012

    Continued strong growth and resolution to distribute TransplantationThird quarterGroup, including discontinuing operations · Sales growth was 17 percent in local currency. Sales amounted to SEK 97 (85) million, corresponding to an increase of 14 percent in SEK. · Sales growth within Fertility was 16 percent in local currency and 13 percent in SEK. Sales growth within Transplantation was 23 percent in local currency and 22 percent in SEK. · Operating income (EBIT) amounted to SEK 13 (14) million. One-time expenses of SEK 5 million were charged against operating income ahead of

    Private placement regarding Cryo Management fully subscribed

    The Extraordinary General Meeting of Vitrolife held on September 24 adopted a resolution regarding a private placement of EUR 1.352.315 in order to partly finance the acquisition of Cryo Management Ltd. In accordance with the resolution, the board of directors of Vitrolife has resolved to determine that the company’s share capital shall be increased with not more than SEK 273.530,34 by an issue of not more than 268,167 shares. The new share issue was fully subscribed.The Extraordinary General Meeting of Vitrolife held September 24 adopted a resolution regarding a private placement of EUR 1.

    Vitrolife completes acquisition of Cryo Management Ltd

    On June 29 Vitrolife announced that the company had entered into an agreement to acquire 100% ownership in Cryo Management Ltd. Vitrolife has now completed the transaction and Cryo Management Ltd is now a part of Vitrolife.Cryo Management Ltd is one of the world’s leading players within time-lapse for IVF, developer of Primo Vision time-lapse embryo monitoring system. The company has approximately 20 employees and is based in Hungary. The acquisition was completed under essentially the same conditions as were communicated on June 29. “We are pleased to be able to welcome our new

    Vitrolife acquires Cryo Management Ltd and thereby broadens the product portfolio

    Vitrolife has entered into an agreement to acquire Cryo Management Ltd, one of the world’s leading players within time-lapse for IVF, developer of Primo Vision time-lapse embryo monitoring system. Through the acquisition Vitrolife gains access to a product portfolio in the form of successful time-lapse products for IVF and increased knowledge within IVF technology and embryo development.Vitrolife has entered into an agreement to acquire 100% ownership in Cryo Management Ltd by September for a purchase sum of EUR 5 million, which can be increased to EUR 9 million upon the fulfilment of

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe